Company intelligence / Profile preview

AzurBio Pharma

Paris, Île-de-France, Franceazurbio-pharma.com ↗

Ownership: Private
Development stage: Other

Overview

AzurBio Pharma is a Paris-based company launched in late 2024 that specializes in helping biopharmaceutical companies—especially those with innovative treatments for rare or serious diseases—navigate the complex European regulatory landscape. Its core offerings include strategic partnerships, turnkey market access solutions, and early access program facilitation to accelerate time-to-market in Europe, particularly leveraging France’s unique early access pathways. The company does not develop its own drugs but acts as an expert partner to streamline registration through commercialization for clients seeking EU entry

Therapeutic areas: Rare Diseases
Industry: Consulting

Partnerships

Not specifically disclosed; works with North American and global biopharmaceutical companies seeking EU market entry

Beyond the preview

Go deeper on AzurBio Pharma.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AzurBio Pharma.

Explore the full profile